CHS-007-01/ RTOG Foundation Study 3521
Study Date: April 1, 2024 | Status: Open to Accrual
The "TRANSPARENT" Study
TRANSPARENT: Single-Arm Study of Toripalimab in Combination with Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Naïve Participants
Principal Investigator
Anna Spreafico, MD
Primary Objective
To evaluate the efficacy of toripalimab in combination with chemotherapy (cisplatin and gemcitabine), as measured by objective response rate (ORR) assessed by a Blinded Independent Central Review Committee (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1.
Patient Population
Patients with recurrent, metastatic nasopharyngeal cancer with either Epstein-Barr virus (EBV)-associated or non-EBV associated disease.
Participating Sites
| Institution Name | City | State/Country |
|---|---|---|
| Boston Medical Center | Boston | MA |
| Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine | CA |
| Emory University | Atlanta | GA |
| Laura and Isaac Perlmutter Cancer Center, NYU Langone | New York | NY |
| UC Irvine Medical Center | Orange | CA |
| University Health Network - Princess Margaret Hospital | Toronto | Canada |
| University of Arkansas for Medical Sciences | Little Rock | AR |
| University of California, San Francisco | San Francisco | CA |